SOAT1 and myeloproliferative neoplasm: More compelling evidence that inhibition of the JAK-STAT pathway does not prevent progression to MPN-BP comes from a clonal evolution study of 15 JAKi treated patients where whole-exome sequencing was performed at multiple time points during treatment, allowing for monitoring of clonal evolution over time.